{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:03:47Z","timestamp":1791745427456,"version":"4.3.4"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00210-026-05006-4","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:13:32Z","timestamp":1769555612000},"page":"9437-9451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the therapeutic potential of withaferin A by modulating key oncosignaling pathways"],"prefix":"10.1007","volume":"399","author":[{"given":"Prashant","family":"Chauhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Nasar","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safia Obaidur","family":"Rab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadwa Mohammed","family":"Alkhulaifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorabh","family":"Lakhanpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"4","key":"5006_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/1566524023666230418094708","volume":"24","author":"P Abeesh","year":"2024","unstructured":"Abeesh P, Guruvayoorappan C (2024) The therapeutic effects of withaferin A against cancer: overview and updates. Curr Mol Med 24(4):404\u2013418","journal-title":"Curr Mol Med"},{"issue":"1","key":"5006_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2021.112335","volume":"128","author":"P Abeesh","year":"2021","unstructured":"Abeesh P, Vishnu WK, Guruvayoorappan C (2021) Preparation and characterization of withaferin A loaded pegylated nanoliposomal formulation with high loading efficacy: in vitro and in vivo anti-tumour study. Mater Sci Eng, C 128(1):112335","journal-title":"Mater Sci Eng, C"},{"issue":"1","key":"5006_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2023.213661","volume":"154","author":"P Abeesh","year":"2023","unstructured":"Abeesh P, Bouvet P, Guruvayoorappan C (2023) AS1411 aptamer tagged PEGylated liposomes as a smart nanocarrier for tumor-specific delivery of withaferin A for mitigating pulmonary metastasis. Biomater Adv 154(1):213661","journal-title":"Biomater Adv"},{"key":"5006_CR4","doi-asserted-by":"crossref","unstructured":"Acosta JC, Barua A. Abstract C055: withaferin A offers novel targeted immunotherapy against high-grade serous ovarian carcinoma. Molecular cancer therapeutics. 2023 Dec 1;22(12_Supplement):C055-.","DOI":"10.1158\/1535-7163.TARG-23-C055"},{"issue":"10","key":"5006_CR5","first-page":"155","volume":"4","author":"S Ahmed","year":"2015","unstructured":"Ahmed S, Hasan MM (2015) Standardization of crude drugs: a precise review. World J Pharm Res 4(10):155\u2013174","journal-title":"World J Pharm Res"},{"key":"5006_CR6","doi-asserted-by":"crossref","unstructured":"Ahmed S, Alam W, Aschner M, Alsharif KF, Albrakati A, Saso L, Khan H (2022) Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy. Biomed Pharmacother 1(155):113797","DOI":"10.1016\/j.biopha.2022.113797"},{"issue":"5","key":"5006_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/ph17050574","volume":"17","author":"G Albahri","year":"2024","unstructured":"Albahri G, Badran A, Abdel Baki Z, Alame M, Hijazi A, Daou A, Baydoun E (2024) Potential anti-tumorigenic properties of diverse medicinal plants against the majority of common types of cancer. Pharmaceuticals 17(5):574","journal-title":"Pharmaceuticals"},{"issue":"3","key":"5006_CR8","first-page":"799","volume":"10","author":"AM Alnuqaydan","year":"2020","unstructured":"Alnuqaydan AM, Rah B, Almutary AG, Chauhan SS (2020Mar 1) Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress-mediated autophagy and apoptosis in colorectal cancer cells. Am J Cancer Res 10(3):799","journal-title":"Am J Cancer Res"},{"issue":"1","key":"5006_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.canlet.2013.02.032","volume":"334","author":"F Aqil","year":"2013","unstructured":"Aqil F, Munagala R, Jeyabalan J, Vadhanam MV (2013) Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett 334(1):133\u2013141","journal-title":"Cancer Lett"},{"issue":"13","key":"5006_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.975320","volume":"19","author":"M Atteeq","year":"2022","unstructured":"Atteeq M (2022) Evaluating anticancer properties of withaferin A\u2014a potent phytochemical. Front Pharmacol 19(13):975320","journal-title":"Front Pharmacol"},{"issue":"1","key":"5006_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/jclinpath-2018-205370","volume":"72","author":"AC Bateman","year":"2019","unstructured":"Bateman AC (2019) Molecules in cancer immunotherapy: benefits and side effects. J Clin Pathol 72(1):20\u201324","journal-title":"J Clin Pathol"},{"issue":"2","key":"5006_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.tips.2004.12.002","volume":"26","author":"MV Blagosklonny","year":"2005","unstructured":"Blagosklonny MV (2005) Overcoming limitations of natural anticancer drugs by combining with artificial agents. Trends Pharmacol Sci 26(2):77\u201381","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"5006_CR13","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/ijms26031210","volume":"26","author":"A Brane","year":"2025","unstructured":"Brane A, Sutko M, Tollefsbol TO (2025) p21 promoter methylation is vital for the anticancer activity of withaferin A. Int J Mol Sci 26(3):1210","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5006_CR14","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.7314\/APJCP.2014.15.4.1711","volume":"15","author":"Y Cai","year":"2014","unstructured":"Cai Y, Sheng ZY, Chen Y, Bai C (2014) Effect of withaferin A on A549 cellular proliferation and apoptosis in non-small cell lung cancer. Asian Pac J Cancer Prev 15(4):1711\u20131714","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"5006_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3329\/bjp.v9i3.19568","volume":"9","author":"Y Chen","year":"2014","unstructured":"Chen Y, Han XZ, Wang W, Zhao RT, Li X (2014) Withaferin A inhibits osteosarcoma cells through inactivation of Notch-1 signalling. Bangladesh Journal of Pharmacology 9(3):364\u2013370","journal-title":"Bangladesh Journal of Pharmacology"},{"issue":"3","key":"5006_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.15430\/JCP.2015.20.3.185","volume":"20","author":"BY Choi","year":"2015","unstructured":"Choi BY, Kim BW (2015) Withaferin-A inhibits colon cancer cell growth by blocking STAT3 transcriptional activity. J Cancer Prev 20(3):185","journal-title":"J Cancer Prev"},{"issue":"6","key":"5006_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.amjsurg.2012.07.027","volume":"204","author":"SM Cohen","year":"2012","unstructured":"Cohen SM, Mukerji R, Timmermann BN, Samadi AK, Cohen MS (2012) A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. The American Journal of Surgery 204(6):895\u2013901","journal-title":"The American Journal of Surgery"},{"issue":"9","key":"5006_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4573","volume":"33","author":"T Dai","year":"2019","unstructured":"Dai T, Jiang W, Guo Z, Wang Z, Huang M, Zhong G, Liang C, Pei X, Dai R (2019) Studies on oral bioavailability and first\u2010pass metabolism of withaferin A in rats using LC\u2013MS\/MS and Q\u2010TRAP. Biomed Chromatogr 33(9):e4573","journal-title":"Biomed Chromatogr"},{"key":"5006_CR19","doi-asserted-by":"crossref","unstructured":"Devabattula G, Panda B, Yadav R, Godugu C. The potential pharmacological effects of natural product withaferin A in cancer: opportunities and challenges for clinical translation. Planta Medica. 2024 Apr 8.","DOI":"10.1055\/a-2289-9600"},{"issue":"5","key":"5006_CR20","first-page":"32","volume":"38","author":"PU Devi","year":"2000","unstructured":"Devi PU, Kamath R, Rao BS (2000) Radiosensitization of a mouse melanoma by withaferin A: in vivo studies. Indian J Exp Biol 38(5):32\u20137","journal-title":"Indian Journal of Experimental Biology"},{"key":"5006_CR21","doi-asserted-by":"crossref","unstructured":"Effect of Withaferin A on A549 Cellular proliferation and apoptosis in non-small cell lung cancer. Asian Pacific Journal of Cancer Prevention, 2014; 15(4): 1711\u20131714.","DOI":"10.7314\/APJCP.2014.15.4.1711"},{"key":"5006_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042265","author":"MY Fong","year":"2012","unstructured":"Fong MY, Jin S, Rane M, Singh RK, Gupta R, Kakar SS (2012) Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0042265","journal-title":"PLoS One"},{"key":"5006_CR23","first-page":"1","volume":"6","author":"AK Goyal","year":"2025","unstructured":"Goyal AK, Saini J, Bakshi J, Alnemare AK, Mahfoz TB (2025) Prevalence, incidence, and mortality trends of head and neck cancers in India: a GLOBOCAN 2022 statistics analysis. Indian J Surg Oncol 6:1","journal-title":"Indian J Surg Oncol"},{"issue":"1","key":"5006_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10637-013-9987-y","volume":"32","author":"M Gu","year":"2013","unstructured":"Gu M, Yu Y, Gunaherath GMKB, Gunatilaka AAL, Li D, Sun D (2013) Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells. Invest New Drugs 32(1):68\u201374","journal-title":"Invest New Drugs"},{"issue":"1","key":"5006_CR25","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.toxrep.2022.05.012","volume":"9","author":"SK Gupta","year":"2022","unstructured":"Gupta SK, Jadhav S, Gohil D, Panigrahi GC, Kaushal RK, Gandhi K, Patil A, Chavan P, Gota V (2022) Safety, toxicity and pharmacokinetic assessment of oral withaferin-A in mice. Toxicol Rep 9(1):1204\u20131212","journal-title":"Toxicol Rep"},{"issue":"11","key":"5006_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mc.22050","volume":"53","author":"ER Hahm","year":"2014","unstructured":"Hahm ER, Lee J, Singh SV (2014) Role of mitogen\u2010activated protein kinases and Mcl\u20101 in apoptosis induction by withaferin A in human breast cancer cells. Mol Carcinog 53(11):907\u2013916","journal-title":"Mol Carcinog"},{"issue":"8","key":"5006_CR27","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamainternmed.2020.2250","volume":"180","author":"T Hilal","year":"2020","unstructured":"Hilal T, Gonzalez-Velez M, Prasad V (2020) Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration. JAMA Intern Med 180(8):1108\u20131115","journal-title":"JAMA Intern Med"},{"issue":"2","key":"5006_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.21010\/ajtcam.v14i2.33","volume":"14","author":"WC Hou","year":"2017","unstructured":"Hou WC, Miao XH, Ma LJ, Bai XX, Liu Q, Song L (2017) Withaferin A induces apoptosis in rat C6 glioma cells through regulating NF-\u03baB nuclear translocation and activation of caspase cascade. Afr J Tradit Complement Altern Med 14(2):319\u2013324","journal-title":"Afr J Tradit Complement Altern Med"},{"issue":"7","key":"5006_CR29","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3390\/cancers11071003","volume":"11","author":"JH Hsu","year":"2019","unstructured":"Hsu JH, Chang PM, Cheng TS, Kuo YL, Wu AT, Tran TH, Yang YH, Chen JM, Tsai YC, Chu YS, Huang TH (2019) Identification of withaferin A as a potential candidate for anti-cancer therapy in non-small cell lung cancer. Cancers 11(7):1003","journal-title":"Cancers"},{"issue":"177","key":"5006_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117080","volume":"1","author":"S Hua","year":"2024","unstructured":"Hua S, Gu X, Jin H, Zhang X, Liu Q, Yang J (2024) Tumor-infiltrating T lymphocytes: a promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma. Biomed Pharmacother 1(177):117080","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"5006_CR31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.bbrc.2012.06.047","volume":"423","author":"SS Kakar","year":"2012","unstructured":"Kakar SS, Jala VR, Fong MY (2012) Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines. Biochem Biophys Res Commun 423(4):819\u2013825","journal-title":"Biochem Biophys Res Commun"},{"issue":"19","key":"5006_CR32","volume":"4","author":"SS Kakar","year":"2016","unstructured":"Kakar SS, Worth CA, Wang Z, Carter K, Ratajczak M, Gunjal P (2016) DOXIL when combined with withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer. J Cancer Stem Cell Res 4(19):e1002","journal-title":"J Cancer Stem Cell Res"},{"issue":"4","key":"5006_CR33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1177\/1534735410378664","volume":"9","author":"G Kalthur","year":"2010","unstructured":"Kalthur G, Pathirissery UD (2010) Enhancement of the response of B16F1 melanoma to fractionated radiotherapy and prolongation of survival by withaferin A and\/or hyperthermia. Integr Cancer Ther 9(4):370\u2013377","journal-title":"Integr Cancer Ther"},{"issue":"6","key":"5006_CR34","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/pca.2968","volume":"31","author":"M Karimi","year":"2020","unstructured":"Karimi M, Raofie F (2020) Preparation of withaferin A nanoparticles extracted from Withania somnifera by the expansion of supercritical fluid solution. Phytochem Anal 31(6):957\u2013967","journal-title":"Phytochem Anal"},{"issue":"12","key":"5006_CR35","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.3390\/cancers15123089","volume":"15","author":"R Khalil","year":"2023","unstructured":"Khalil R, Green RJ, Sivakumar K, Varandani P, Bharadwaj S, Mohapatra SS, Mohapatra S (2023) Withaferin a increases the effectiveness of immune checkpoint blocker for the treatment of non-small cell lung cancer. Cancers 15(12):3089","journal-title":"Cancers"},{"key":"5006_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10549-016-3795-y","volume":"157","author":"SH Kim","year":"2016","unstructured":"Kim SH, Hahm ER, Arlotti JA, Samanta SK, Moura MB, Thorne SH, Shuai Y, Anderson CJ, White AG, Lokshin A, Lee J (2016) Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown. Breast Cancer Res Treat 157:41\u201354","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"5006_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/1535-7163.MCT-09-0771","volume":"9","author":"S Koduru","year":"2010","unstructured":"Koduru S, Kumar R, Srinivasan S, Evers MB, Damodaran C (2010) Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther 9(1):202\u2013210","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"5006_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"A Kreso","year":"2014","unstructured":"Kreso A, Dick JE (2014) Evolution of the cancer stem cell model. Cell Stem Cell 14(3):275\u2013291","journal-title":"Cell Stem Cell"},{"issue":"1","key":"5006_CR39","doi-asserted-by":"publisher","first-page":"15737","DOI":"10.1038\/s41598-018-34018-1","volume":"8","author":"AH Kyakulaga","year":"2018","unstructured":"Kyakulaga AH, Aqil F, Munagala R, Gupta RC (2018) Withaferin A inhibits epithelial to mesenchymal transition in non-small cell lung cancer cells. Sci Rep 8(1):15737","journal-title":"Sci Rep"},{"issue":"16","key":"5006_CR40","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.18632\/oncotarget.27519","volume":"11","author":"AH Kyakulaga","year":"2020","unstructured":"Kyakulaga AH, Aqil F, Munagala R, Gupta RC (2020) Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells. Oncotarget 11(16):1399","journal-title":"Oncotarget"},{"issue":"11","key":"5006_CR41","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1093\/carcin\/bgq175","volume":"31","author":"J Lee","year":"2010","unstructured":"Lee J, Hahm ER, Singh SV (2010) Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. Carcinogenesis 31(11):1991\u20131998","journal-title":"Carcinogenesis"},{"key":"5006_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10549-012-2239-6","volume":"136","author":"J Lee","year":"2012","unstructured":"Lee J, Sehrawat A, Singh SV (2012) Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat 136:45\u201356","journal-title":"Breast Cancer Res Treat"},{"key":"5006_CR43","doi-asserted-by":"crossref","unstructured":"Li W, Sahu D, Tsen F. Secreted heat shock protein-90 (Hsp90) in wound healing and cancer. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2012 Mar 1;1823(3):730\u201341.","DOI":"10.1016\/j.bbamcr.2011.09.009"},{"issue":"1","key":"5006_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.canlet.2014.11.026","volume":"357","author":"XU Li","year":"2015","unstructured":"Li XU, Zhu F, Jiang J, Sun C, Wang X, Shen M, Tian R, Shi C, Xu M, Peng F, Guo X (2015) Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K\/AKT pathway in human pancreatic cancer cells. Cancer Lett 357(1):219\u2013230","journal-title":"Cancer Lett"},{"issue":"1","key":"5006_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/08923973.2023.2247552","volume":"46","author":"J Li","year":"2024","unstructured":"Li J, Ge M, Deng P, Wu X, Shi L, Yang Y (2024) Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3\/FOXO1\/JAK2\/STAT3 pathway-mediated ROS production. Immunopharmacol Immunotoxicol 46(1):40\u201348","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"5006_CR46","doi-asserted-by":"crossref","unstructured":"Lu WQ, Li XD, Gu Y, Huang JM, Qin YK, Cai XY, Wang CM. Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90\/HIF-1\u03b1\/EMT axis. Archives of Medical Science. 2025.","DOI":"10.5114\/aoms\/196381"},{"issue":"1","key":"5006_CR47","first-page":"1","volume":"15","author":"P Lu","year":"2025","unstructured":"Lu P, Xue J, Ji X (2025) Radiosensitizing effects of Withaferin A in gastric cancer cells via autophagy Inhibition and mitochondrial disruption. Sci Rep 15(1):1\u20133","journal-title":"Sci Rep"},{"issue":"2","key":"5006_CR48","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s12668-020-00819-w","volume":"11","author":"S Madhu","year":"2021","unstructured":"Madhu S, Komala M, Pandian P (2021) Formulation development and characterization of withaferin-A loaded polymeric nanoparticles for Alzheimer\u2019s disease. BioNanoScience 11(2):559\u2013566","journal-title":"BioNanoScience"},{"issue":"1","key":"5006_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.7861\/clinmed.2022-0589","volume":"23","author":"P Mahalingam","year":"2023","unstructured":"Mahalingam P, Newsom-Davis T (2023) Cancer immunotherapy and the management of side effects. Clin Med 23(1):56\u201360","journal-title":"Clin Med"},{"issue":"12","key":"5006_CR50","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1007\/s10495-008-0271-0","volume":"13","author":"C Mandal","year":"2008","unstructured":"Mandal C, Dutta A, Mallick A, Chandra S, Misra L, Sangwan RS, Mandal C (2008) Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. Apoptosis 13(12):1450\u20131464","journal-title":"Apoptosis"},{"issue":"5","key":"5006_CR51","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3390\/molecules27051476","volume":"27","author":"SJ Modi","year":"2022","unstructured":"Modi SJ, Tiwari A, Ghule C, Pawar S, Saste G, Jagtap S, Singh R, Deshmukh A, Girme A, Hingorani L (2022Feb 22) Pharmacokinetic study of withanosides and withanolides from Withania somnifera using ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS\/MS). Molecules 27(5):1476","journal-title":"Molecules"},{"issue":"3","key":"5006_CR52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41419-024-06524-w","volume":"15","author":"N Mukherjee","year":"2024","unstructured":"Mukherjee N, Katsnelson E, Brunetti TM, Michel K, Couts KL, Lambert KA, Robinson WA, McCarter MD, Norris DA, Tobin RP, Shellman YG (2024) MCL1 inhibition targets myeloid derived suppressors cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade. Cell Death Dis 15(3):198","journal-title":"Cell Death Dis"},{"issue":"3","key":"5006_CR53","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","volume":"83","author":"DJ Newman","year":"2020","unstructured":"Newman DJ, Cragg GM (2020) Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019. J Nat Prod 83(3):770\u2013803","journal-title":"J Nat Prod"},{"key":"5006_CR54","first-page":"1","volume":"30","author":"MF Nisar","year":"2024","unstructured":"Nisar MF, Wan C, B\u00fcsselberg D, Calina D, Sharifi-Rad J (2024) Current mechanistic insights into Withaferin A: a promising potential adjuvant anticancer agent from Withania somnifera. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 30:1\u201321","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"4","key":"5006_CR55","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1007\/s00210-024-03662-y","volume":"398","author":"MF Nisar","year":"2025","unstructured":"Nisar MF, Wan C, B\u00fcsselberg D, Calina D, Sharifi-Rad J (2025) Current mechanistic insights into withaferin A: a promising potential adjuvant anticancer agent from Withania somnifera. Naunyn-Schmiedebergs Arch Pharmacol 398(4):3573\u20133593","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"5006_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jaim.2015.08.001","volume":"7","author":"SB Patel","year":"2016","unstructured":"Patel SB, Rao NJ, Hingorani LL (2016) Safety assessment of Withania somnifera extract standardized for withaferin A: acute and sub-acute toxicity study. Journal of Ayurveda and Integrative Medicine 7(1):30\u201337","journal-title":"Journal of Ayurveda and Integrative Medicine"},{"issue":"80","key":"5006_CR57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jpba.2013.03.001","volume":"1","author":"D Patil","year":"2013","unstructured":"Patil D, Gautam M, Mishra S, Karupothula S, Gairola S, Jadhav S, Pawar S, Patwardhan B (2013) Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral administration of Withania somnifera aqueous extract. J Pharm Biomed Anal 1(80):203\u2013212","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"5006_CR58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaim.2018.12.008","volume":"11","author":"N Pires","year":"2020","unstructured":"Pires N, Gota V, Gulia A, Hingorani L, Agarwal M, Puri A (2020) Safety and pharmacokinetics of withaferin-A in advanced stage high grade osteosarcoma: a phase I trial. Journal of Ayurveda and Integrative Medicine 11(1):68\u201372","journal-title":"Journal of Ayurveda and Integrative Medicine"},{"issue":"12","key":"5006_CR59","first-page":"1622588","volume":"16","author":"Z Qu","year":"2025","unstructured":"Qu Z, Wu Y, Fan Q, Zhou W, Liu M (2025) The relationship between oxidative balance score (OBS), depression, and survival among adult cancer survivors in the United States. Front Nutr 16(12):1622588","journal-title":"Front Nutr"},{"issue":"2","key":"5006_CR60","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/15548627.2015.1017182","volume":"11","author":"B Rah","year":"2015","unstructured":"Rah B, Rasool RU, Nayak D, Yousuf SK, Mukherjee D, Kumar LD, Goswami A (2015) PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells. Autophagy 11(2):314\u2013331","journal-title":"Autophagy"},{"issue":"1","key":"5006_CR61","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s40495-024-00384-w","volume":"11","author":"A Ramachandran","year":"2024","unstructured":"Ramachandran A, Sivaprakasam P, Chan Basha YB, Pandurangan AK (2024) The therapeutic potential of Withania somnifera in breast cancer: a comprehensive review. Current Pharmacology Reports 11(1):2","journal-title":"Current Pharmacology Reports"},{"key":"5006_CR62","doi-asserted-by":"crossref","unstructured":"Sarwar R, Maisam M, Khan MW, Xue Y, Hassan S. Bioactive compounds in herbal remedies. In Herbal pharmacopeia 2025 (pp. 89\u2013121). CRC Press.","DOI":"10.1201\/9781003544418-5"},{"issue":"5","key":"5006_CR63","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3390\/pr13051290","volume":"13","author":"V Sekar","year":"2025","unstructured":"Sekar V, Santhanam A, Arunkumar P (2025) pH-responsive gold nanoparticle\/PVP nanoconjugate for targeted delivery and enhanced anticancer activity of withaferin A. Processes 13(5):1290","journal-title":"Processes"},{"issue":"7","key":"5006_CR64","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1349-7006.2006.00224.x","volume":"97","author":"P Senthilnathan","year":"2006","unstructured":"Senthilnathan P, Padmavathi R, Magesh V, Sakthisekaran D (2006) Chemotherapeutic efficacy of paclitaxel in combination with Withania somnifera on benzo (a) pyrene\u2010induced experimental lung cancer. Cancer Sci 97(7):658\u2013664","journal-title":"Cancer Sci"},{"issue":"1","key":"5006_CR65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3109\/02841869609098486","volume":"35","author":"AC Sharada","year":"1996","unstructured":"Sharada AC, Solomon FE, Devi PU, Udupa N, Srinivasan KK (1996) Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. Acta Oncol 35(1):95\u2013100","journal-title":"Acta Oncol"},{"issue":"1","key":"5006_CR66","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12935-023-03174-4","volume":"23","author":"F Sheikhnia","year":"2023","unstructured":"Sheikhnia F, Rashidi V, Maghsoudi H, Majidinia M (2023) Potential anticancer properties and mechanisms of thymoquinone in colorectal cancer. Cancer Cell Int 23(1):320","journal-title":"Cancer Cell Int"},{"key":"5006_CR67","doi-asserted-by":"crossref","unstructured":"Sheikhnia F, Fazilat A, Rashidi V, Azizzadeh B, Mohammadi M, Maghsoudi H, Majidinia M (2024Aug) Exploring the therapeutic potential of quercetin in cancer treatment: targeting long non-coding RNAs. Pathology-Research and Practice 1(260):155374","DOI":"10.1016\/j.prp.2024.155374"},{"issue":"1","key":"5006_CR68","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5006_CR69","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025Jan 16) Cancer statistics, 2025. Ca 75(1):10","journal-title":"Ca"},{"issue":"155","key":"5006_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108128","volume":"1","author":"SK Singh","year":"2025","unstructured":"Singh SK, Rashid M, Chaturvedi S, Agarwal A, Chauhan D, Gayen JR, Wahajuddin M (2025Feb) Preclinical pharmacokinetics, absolute bioavailability and dose proportionality evaluation of bioactive phytochemical withanone in rats. Bioorg Chem 1(155):108128","journal-title":"Bioorg Chem"},{"issue":"18","key":"5006_CR71","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-08-1510","volume":"68","author":"SD Stan","year":"2008","unstructured":"Stan SD, Hahm ER, Warin R, Singh SV (2008) Withaferin A causes FOXO3a-and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Can Res 68(18):7661\u20137669","journal-title":"Can Res"},{"issue":"12","key":"5006_CR72","doi-asserted-by":"publisher","first-page":"13854","DOI":"10.18632\/oncotarget.7351","volume":"7","author":"S Suman","year":"2016","unstructured":"Suman S, Das TP, Sirimulla S, Alatassi H, Ankem MK, Damodaran C (2016) Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells. Oncotarget 7(12):13854","journal-title":"Oncotarget"},{"issue":"33","key":"5006_CR73","doi-asserted-by":"publisher","first-page":"53751","DOI":"10.18632\/oncotarget.10733","volume":"7","author":"S Suman","year":"2016","unstructured":"Suman S, Das TP, Moselhy J, Pal D, Kolluru V, Alatassi H, Ankem MK, Damodaran C (2016a) Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model. Oncotarget 7(33):53751","journal-title":"Oncotarget"},{"issue":"9","key":"5006_CR74","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3390\/biom14091178","volume":"14","author":"R Szydlak","year":"2024","unstructured":"Szydlak R (2024) Synergistic inhibition of pancreatic cancer cell growth and migration by gemcitabine and withaferin A. Biomolecules 14(9):1178","journal-title":"Biomolecules"},{"key":"5006_CR75","unstructured":"Tian H. Withaferin A attenuates epithelial-mesenchymal transition and cancer stem cells properties in hepatocellular carcinoma cells by inhibiting the PI3K\/AKT pathway through miR-200c. Pharmacognosy magazine. 2022;18(80)."},{"issue":"1","key":"5006_CR76","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bbrc.2012.08.133","volume":"427","author":"HJ Um","year":"2012","unstructured":"Um HJ, Min KJ, Kim DE, Kwon TK (2012) Withaferin A inhibits JAK\/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells. Biochem Biophys Res Commun 427(1):24\u201329","journal-title":"Biochem Biophys Res Commun"},{"key":"5006_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-013-9531-1","volume":"16","author":"AR Vyas","year":"2014","unstructured":"Vyas AR, Singh SV (2014) Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone. AAPS J 16:1\u20130","journal-title":"AAPS J"},{"issue":"17","key":"5006_CR78","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.3390\/cancers16173090","volume":"16","author":"R Wadhwa","year":"2024","unstructured":"Wadhwa R, Wang J, Shefrin S, Zhang H, Sundar D, Kaul SC (2024) Molecular insights into the anticancer activity of withaferin-A: the inhibition of survivin signaling. Cancers 16(17):3090","journal-title":"Cancers"},{"key":"5006_CR79","doi-asserted-by":"crossref","unstructured":"Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, Sarkar FH. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochimica et Biophysica Acta (BBA)-reviews on cancer. 2010 Dec 1;1806(2):258\u201367.","DOI":"10.1016\/j.bbcan.2010.06.001"},{"key":"5006_CR80","doi-asserted-by":"crossref","unstructured":"Wang YJ, Liu SY, Lai JM (2024) Enhancing cancer therapy: synergistic effects of withaferin A and ionizing radiation on lung cancer cells. Int J Radiat Oncol Biol Phys 120(2):e410","DOI":"10.1016\/j.ijrobp.2024.07.912"},{"key":"5006_CR81","doi-asserted-by":"crossref","unstructured":"Wei H, Zhang Y, Jia Y, Chen X, Niu T, Chatterjee A, et al. Heat shock protein 90: biological functions, diseases, and therapeutic targets. MedComm. 2024 Jan 25;5(2).","DOI":"10.1002\/mco2.470"},{"issue":"5","key":"5006_CR82","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1124\/dmd.121.000455","volume":"50","author":"Y Xia","year":"2022","unstructured":"Xia Y, Yan M, Wang P, Hamada K, Yan N, Hao H, Gonzalez FJ, Yan T (2022) Withaferin A in the treatment of liver diseases: progress and pharmacokinetic insights. Drug Metab Dispos 50(5):685\u2013693","journal-title":"Drug Metab Dispos"},{"key":"5006_CR83","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.2147\/DDDT.S422512","volume":"31","author":"Z Xing","year":"2023","unstructured":"Xing Z, Su A, Mi L, Zhang Y, He T, Qiu Y, Wei T, Li Z, Zhu J, Wu W (2023) Withaferin A: a dietary supplement with promising potential as an anti-tumor therapeutic for cancer treatment-pharmacology and mechanisms. Drug des Dev Ther 31:2909\u20132929","journal-title":"Drug des Dev Ther"},{"issue":"7","key":"5006_CR84","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-021-02878-6","volume":"11","author":"K Xu","year":"2021","unstructured":"Xu K, Shi H, Du Y, Ou J (2021) Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-\u03b2 (TGF-\u03b2) signalling. 3 Biotech 11(7):323","journal-title":"3 Biotech"},{"issue":"8","key":"5006_CR85","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.tiv.2011.09.016","volume":"25","author":"ES Yang","year":"2011","unstructured":"Yang ES, Choi MJ, Kim JH, Choi KS, Kwon TK (2011) Combination of withaferin A and X-ray irradiation enhances apoptosis in U937 cells. Toxicol in Vitro 25(8):1803\u20131810","journal-title":"Toxicol in Vitro"},{"issue":"1","key":"5006_CR86","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cbi.2011.01.015","volume":"190","author":"ES Yang","year":"2011","unstructured":"Yang ES, Choi MJ, Kim JH, Choi KS, Kwon TK (2011a) Withaferin A enhances radiation-induced apoptosis in Caki cells through induction of reactive oxygen species, Bcl-2 downregulation and Akt inhibition. Chem Biol Interact 190(1):9\u201315","journal-title":"Chem Biol Interact"},{"key":"5006_CR87","doi-asserted-by":"publisher","DOI":"10.4137\/BCI.S18863","volume":"7","author":"LP Yco","year":"2014","unstructured":"Yco LP, Mocz G, Opoku-Ansah J, Bachmann AS (2014) Withaferin A inhibits STAT3 and induces tumor cell death in neuroblastoma and multiple myeloma. Biochem Insights 7:BCI-S18863","journal-title":"Biochem Insights"},{"issue":"1","key":"5006_CR88","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nri1995","volume":"7","author":"H Yu","year":"2007","unstructured":"Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7(1):41\u201351","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"5006_CR89","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.bcp.2009.09.017","volume":"79","author":"Y Yu","year":"2010","unstructured":"Yu Y, Hamza A, Zhang T, Gu M, Zou P, Newman B, Li Y, Gunatilaka AL, Zhan CG, Sun D (2010) Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 79(4):542\u2013551","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"5006_CR90","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ygyno.2011.11.044","volume":"124","author":"X Zhang","year":"2012","unstructured":"Zhang X, Samadi AK, Roby KF, Timmermann B, Cohen MS (2012) Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A. Gynecol Oncol 124(3):606\u2013612","journal-title":"Gynecol Oncol"},{"issue":"2","key":"5006_CR91","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/ptr.8090","volume":"38","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Yuan Y, Cao S, Kang N, Qiu F (2024) Withanolides: promising candidates for cancer therapy. Phytother Res 38(2):1104\u20131158","journal-title":"Phytother Res"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05006-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05006-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05006-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:04:11Z","timestamp":1782101051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05006-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":91,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5006"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05006-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}